Restoring dopamine levels

Protein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies

Volumn , Issue , 2007, Pages 415-448

  Nuno Palma, P ^a   Bonifácio, Maria João ^a   Almeida, Luís ^a   Soares Da Silva, Patrício ^a  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056066921     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (144)

1. Acuna, G., Foernzler, D., Leong, D., Rabbia, M., Smit, R., Dorflinger, E. et al. (2002) Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. The Pharmacogenomics Journal, 2, 327-334.
2. Akil, M., Kolachana, B.S., Rothmond, D.A., Hyde, T.M., Weinberger, D.R., and Kleinman, J.E. (2003) Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. Journal of Neuroscience, 23, 2008-2013.
3. Andres, A.M., Soldevila, M., Navarro, A., Kidd, K.K., Oliva, B., and Bertranpetit, J. (2004) Positive selection in MAOA gene is human exclusive: determination of the putative amino acid change selected in the human lineage. Human Genetics, 115, 377-386.
4. Axelrod, J. and Tomchick, R. (1958) Enzymatic O-methylation of epinephrine and other catechols. Journal of Biological Chemistry, 233, 702-705.
5. Bach, A.W., Lan, N.C., Johnson, D.L., Abell, C.W., Bembenek, M.E., Kwan, S.W. et al. (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proceedings of the National Academy of Sciences of the United States of America, 85, 4934-4938.
6. Bäckström, R., Honkanen, E., Pippuri, A., Kairisalo, P., Pystynen, J., Heinola, K. et al. (1989) Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. Journal of Medicinal Chemistry, 32, 841-846.
7. Berry, M.D. (2004) Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. Journal of Neurochemistry, 90, 257-271.
8. Berry, M.D., Juorio, A.V., Li, X.M., and Boulton, A.A. (1996) Aromatic L-amino acid decarboxylase: a neglected and misunderstood enzyme. Neurochemical Research, 21, 1075-1087.
9. Bey, P., Jung, M.J., Koch-Weser, J., Palfreyman, M.G., Sjoerdsma, A., Wagner, J. et al. (1980) Further studies on the inhibition of monoamine synthesis by monofluoromethyldopa. British Journal of Pharmacology, 70, 571-576.
10. Bilder, R.M., Volavka, J., Lachman, H.M., and Grace, A.A. (2004) The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology, 29, 1943-1961.
11. Billett, E.E. (2004) Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology, 25, 139-148.
12. Binda, C., Newton-Vinson, P., Hubalek, F., Edmondson, D.E., and Mattevi, A. (2002) Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nature Structural Biology, 9, 22-26.
13. Binda, C., Li, M., Hubalek, F., Restelli, N., Edmondson, D.E., and Mattevi, A. (2003) Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from highresolution crystal structures. Proceedings of the National Academy of Sciences of the United States of America, 100, 9750-9755.
14. Binda, C., Hubalek, F., Li, M., Edmondson, D.E., and Mattevi, A. (2004a) Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Letters, 564, 225-228.
15. Binda, C., Hubalek, F., Li, M., Herzig, Y., Sterling, J., Edmondson, D.E. et al. (2004b) Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. Journal of Medicinal Chemistry, 47, 1767-1774.
16. Bonifácio, M.J., Vieira-Coelho, M.A., Borges, N., and Soares-da-Silva, P. (2000) Kinetics of rat brain and liver solubilized membrane-bound-catechol-O-methyltransferase. Archives of Biochemistry and Biophysics, 384, 261-367.
17. Bonifacio, M.J., Vieira-Coelho, M.A., and Soares-da-Silva, P. (2003) Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor. European Journal of Pharmacology, 460, 163-170.
18. Bonifati, V. and Meco, G. (1999) New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson’s disease. Pharmacology & Therapeutics, 81, 1-36.
19. Borchardt, R.T., Cheng, C.F., and Cooke, P.H. (1974) The purification and kinetic properties of liver microsomal-catechol-O-methyltransferase. Life Sciences, 14, 1089-1100.
20. Borges, N. (2005) Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy. Expert Opinion in Drug Safety, 4, 69-73.
21. Borgulya, J., Bruderer, H., Bernauer, K., Zurcher, G., and Da Prada, M. (1989) Catechol-Omethyltransferase- inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helvetica Chimica Acta, 72, 952-968.
22. Borroni, E., Cesura, A.M., Gatti, S., and Gasser, R. (2001) A preclinical re-evaluation of the safety profile of tolcapone. Functional Neurology, 16, 125-134.
23. Brooks, D.J., Agid, Y., Eggert, K., Widner, H., Ostergaard, K., and Holopainen, A. (2005) Treatment of end-of-dose wearing-off in Parkinson’s disease: stalevo (levodopa=carbidopa= entacapone) and levodopa=DDCI given in combination with Comtess=Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa= DDCI treatment. European Neurology, 53, 197-202.
24. Burkhard, P., Dominici, P., Borri-Voltattorni, C., Jansonius, J.N., and Malashkevich, V.N. (2001) Structural insight into Parkinson’s disease treatment from drug-inhibited DOPA decarboxylase. Nature Structural Biology, 8, 963-967.
25. Carlsson, A., Lindqvist, M., and Magnusson, T. (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 180, 1200.
26. Castelhano, A.L., Pliura, D.H., Taylor, G.J., Hsieh, K.C., and Krantz, A. (1984) Allenic suicide substrates. New inhibitors of vitamin B6 linked decarboxylases. Journal of the American Chemical Society, 106, 2734-2735.
27. Catto, M., Nicolotti, O., Leonetti, F., Carotti, A., Favia, A.D., Soto-Otero, R. et al. (2006) Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. Journal of Medicinal Chemistry, 49, 4912-4925.
28. Cedarbaum, J.M. (1987) Clinical pharmacokinetics of anti-parkinsonian drugs. Clinical Pharmacokinetics, 13, 141-178.
29. Chase, T.N. (1998) The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs, 55, 1-9.
30. Chen, K. (2004) Organization of MAO A and MAO B promoters and regulation of gene expression. Neurotoxicology, 25, 31-36.
31. Chen, J.J. and Ly, A.V. (2006) Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson’s disease. American Journal of Health-System Pharmacy, 63, 915-928.
32. Chen, J.J. and Swope, D.M. (2005) Clinical pharmacology of rasagiline: a novel, secondgeneration propargylamine for the treatment of Parkinson disease. Journal of Clinical Pharmacology, 45, 878-894.
33. Clarke, A., Brewer, F., Johnson, E.S., Mallard, N., Hartig, F., Taylor, S. et al. (2003) A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. Journal of Neural Transmission, 110, 1241-1255.
34. Cotzias, G.C., Van Woert, M.H., and Schiffer, L.M. (1967) Aromatic amino acids and modification of parkinsonism. New England Journal of Medicine, 276, 374-379.
35. Cotzias, G.C., Papavasiliou, P.S., and Gellene, R. (1969) Modification of Parkinsonism- chronic treatment with L-dopa. New England Journal of Medicine, 280, 337-345.
36. Craig, S.P., Thai, A.L., Weber, M., and Craig, I.W. (1992) Localisation of the gene for human aromatic L-amino acid decarboxylase (DDC) to chromosome 7p13!p11 by in situ hybridisation. Cytogenetics and Cell Genetics, 61, 114-116.
37. Da Prada, M., Kettler, R., Zurcher, G., Schaffner, R., and Haefely, W. (1987) Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. European Neurology Supplement, 27, 9-20.
38. Da Prada, M., Kettler, R., Keller, H.H., Cesura, A.M., Richards, J.G., Saura Marti, J. et al. (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. Journal of Neural Transmission Supplementum, 29, 279-292.
39. De Colibus, L., Li, M., Binda, C., Lustig, A., Edmondson, D.E., and Mattevi, A. (2005) Threedimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proceedings of the National Academy of Sciences of the United States of America, 102, 12684-12689.
40. Deleu, D., Northway, M.G., and Hanssens, Y. (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clinical Pharmacokinetics, 41, 261-309.
41. Dhar, K. and Rosazza, J.P.N. (2000) Purification and characterization of Streptomyces griseus catechol O-methyltransferase. Applied and Environmental Microbiology, 66, 4877-4882.
42. Dingemanse, J., Jorga, K.M., Schmitt, M., Gieschke, R., Fotteler, B., Zurcher, G. et al. (1995) Integrated pharmacokinetics and pharmacodynamics of the novel catechol O-methyltransferase inhibitor tolcapone during first administration to humans. Clinical Pharmacology and Therapeutics, 57, 508-517.
43. Djali, P.K., Dimaline, R., and Dockray, G.J. (1998) Novel form of L-aromatic amino acid decarboxylase mRNA in rat antral mucosa. Experimental Physiology, 83, 617-627.
44. Duchemin, A.M., Berry, M.D., Neff, N.H., and Hadjiconstantinou, M. (2000) Phosphorylation and activation of brain aromatic L-amino acid decarboxylase by cyclic AMP-dependent protein kinase. Journal of Neurochemistry, 75, 725-731.
45. Egan, M., Goldman, D., and Weinberger, D. (2002) The human genome: mutations. American Journal of Psychiatry, 159, 12.
46. Ehringer, H. and Hornykiewicz, O. (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klinische Wochenschrift, 38, 1236-1239.
47. Factor, S.A., Molho, E.S., Feustel, P.J., Brown, D.L., and Evans, S.M. (2001) Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clinical Neuropharmacology, 24, 295-299.
48. Ferreira, J., Rosa, M.M., Coelho, M., Cunha, L., Januário, C., Machado, C. et al. (2006) A double-blind, randomised, placebo- and entacapone-controlled study to investigate the effect of nebicapone (BIA 3-202) on the levodopa pharmacokinetics, COMT activity and motor response in Parkinson disease patients. Movement Disorders, 21 (Suppl 15), S644-S645.
49. Finberg, J.P., Tenne, M., and Youdim, M.B. (1981) Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. British Journal of Pharmacology, 73, 65-74.
50. Fowler, J.S., Volkow, N.D., Logan, J., Wang, G.J., MacGregor, R.R., Schyler, D. et al. (1994) Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse, 18, 86-93.
51. Fowler, J.S., Volkow, N.D., Wang, G.J., Logan, J., Pappas, N., Shea, C. et al. (1997) Agerelated increases in brain monoamine oxidase B in living healthy human subjects. Neurobiology of Aging, 18, 431-435.
52. Fraaije, M.W. and Mattevi, A. (2000) Flavoenzymes: diverse catalysts with recurrent features. Trends in Biochemical Sciences, 25, 126-132.
53. Grossman, M.H., Creveling, C.R., Rybczynski, R., Braverman, M., Isersky, C., and Breakefield, X.O. (1985) Soluble and particulate forms of rat catechol-O-methyltransferase distinguished by gel electrophoresis and immune fixation. Journal of Neurochemistry, 44, 421-432.
54. Guldberg, H.C. and Marsden, C.A. (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacological Reviews, 27, 135-206.
55. Haasio, K., Koponen, A., Penttila, K.E., and Nissinen, E. (2002a) Effects of entacapone and tolcapone on mitochondrial membrane potential. European Journal of Pharmacology, 453, 21-26.
56. Haasio, K., Nissinen, E., Sopanen, L., and Heinonen, E.H. (2002b) Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. Journal of Neural Transmission, 109, 1391-1401.
57. Hadjiconstantinou, M., Duchemin, A.M., and Neff, N.H. (2003) Cyclic GMP-dependent protein kinase phosphorylates and activates brain aromatic L-amino acid decarboxylase. Journal of Neurochemistry, 85, 40-41.
58. Hauptmann, N., Grimsby, J., Shih, J.C., and Cadenas, E. (1996) The metabolism of tyramine by monoamine oxidase A=B causes oxidative damage to mitochondrial DNA. Archives of Biochemistry and Biophysics, 335, 295-304.
59. Heikkinen, H., Saraheimo, M., Antila, S., Ottoila, P., and Pentikainen, P.J. (2001) Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique. European Journal of Clinical Pharmacology, 56, 821-826.
60. Hornykiewicz, O. (2006) The discovery of dopamine deficiency in the parkinsonian brain. Journal of Neural Transmission Supplementum, 70, 9-15.
61. Huotari, M., Santha, M., Lucas, L.R., Karayiorgou, M., Gogos, J.A., and Mannisto, P.T. (2002) Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. Journal of Pharmacology and Experimental Therapeutics, 303, 1309-1316.
62. Ichinose, H., Sumi-Ichinose, C., Ohye, T., Hagino, Y., Fujita, K., and Nagatsu, T. (1992) Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase. Biochemistry, 31, 11546-11550.
63. Jahng, J.W., Wessel, T.C., Houpt, T.A., Son, J.H., and Joh, T.H. (1996) Alternate promoters in the rat aromatic L-amino acid decarboxylase gene for neuronal and nonneuronal expression:an in situ hybridization study. Journal of Neurochemistry, 66, 14-19.
64. Jeffery, D.R. and Roth, J.A. (1984) Characterization of membrane-bound and soluble catechol-Omethyltransferase from human frontal cortex. Journal of Neurochemistry, 42, 826-832.
65. Jeffery, D.R. and Roth, J.A. (1987) Kinetic reaction mechanism for magnesium binding to membrane-bound and soluble catecholO-methyltransferase. Biochemistry, 26, 2955-2958.
66. Jorga, K.M. (1998) Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone:a review of early studies in volunteers. Neurology, 50, S31-S38.
67. Jorga, K., Fotteler, B., Heizmann, P., and Gasser, R. (1999) Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. British Journal of Clinical Pharmacology, 48, 513-520.
68. Keating, G.M. and Lyseng-Williamson, K.A. (2005) Tolcapone: a review of its use in the management of Parkinson’s disease. CNS Drugs, 19, 165-184.
69. Keranen, T., Gordin, A., Karlsson, M., Korpela, K., Pentikainen, P.J., Rita, H. et al. (1994) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. European Journal of Clinical Pharmacology, 46, 151-157.
70. Kim, Y.H., Moody, J.D., Freeman, J.P., Brezna, B., Engesser, K.H., and Cerniglia, C.E. (2004) Evidence for the existence of PAH-quinone reductase and catechol-O-methyltransferase in Mycobacterium vanbaalenii PYR-1. Journal of Industrial Microbiology & Biotechnology, 31, 507-516.
71. Knoll, J. and Magyar, K. (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Advances Biochemistry and Psychopharmacology, 5, 393-408.
72. Korlipara, L.P., Cooper, J.M., and Schapira, A.H. (2004) Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology, 46, 562-569.
73. Larsen, J.P. and Boas, J. (1997) The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian-Danish 5-year study. Norwegian-Danish Study Group. Movement Disorders, 12, 175-182.
74. Lautala, P., Ulmanen, I., and Taskinen, J. (2001) Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Molecular Pharmacology, 59, 393-402.
75. Learmonth, D.A., Vieira-Coelho, M.A., Benes, J., Alves, P.C., Borges, N., Freitas, A.P. et al. (2002) Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. Journal of Medicinal Chemistry, 45, 685-695.
76. Learmonth, D.A., Palma, P.N., Vieira-Coelho, M.A., and Soares-da-Silva, P. (2004) Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. Journal of Medicinal Chemistry, 47, 6207-6217.
77. Legrand, M., Fritig, B., and Hirth, L. (1976) Catechol O-methyltransferases of tobacco:evidence for several enzymes with para- and meta-O-methylating activities. FEBS Letters, 70, 131-136.
78. Lotta, T., Taskinen, J., Backstrom, R., and Nissinen, E. (1992) PLS modelling of structureactivity relationships of catechol O-methyltransferase inhibitors. Journal of Computer-Aided Molecular Design, 6, 253-272.
79. Lotta, T., Vidgren, J., Tilgmann, C., Ulmanen, I., Melen, K., Julkunen, I. et al. (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry, 34, 4202-4210.
80. Loureiro, A.I., Bonifacio, M.J., Fernandes-Lopes, C., Almeida, L., Wright, L.C., and Soares-Da-Silva, P. (2006) Human metabolism of nebicapone (BIA 3-202), a novel catecholo- methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34, 1856-1862.
81. Lundström, K., Salminen, M., Jalanko, A., Savolainen, R., and Ulmanen, I. (1991) Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA and Cell Biology, 10, 181-189.
82. Ma, J., Yoshimura, M., Yamashita, E., Nakagawa, A., Ito, A., and Tsukihara, T. (2004) Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. Journal of Molecular Biology, 338, 103-114.
83. Mahmood, I. (1997) Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clinical Pharmacokinetics, 33, 91-102.
84. Männistö, P.T. and Kaakkola, S. (1989) New selective COMT inhibitors: useful adjuncts for Parkinson’s disease? Trends in Pharmacological Sciences, 10, 54-56.
85. Männistö, P.T. and Kaakkola, S. (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacology & Toxicology, 66, 317-323.
86. Männistö, P.T. and Kaakkola, S. (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacological Reviews, 51, 593-628.
87. Männistö, P.T., Tuomainen, P., and Tuominen, R.K. (1992a) Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. British Journal of Pharmacology, 105, 569-574.
88. Männistö, P.T., Ulmanen, I., Lundstrom, K., Taskinen, J., Tenhunen, J., Tilgmann, C. et al. (1992b) Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Progress in Drug Research, 39, 291-350.
89. Maycock, A.L., Aster, S.D., and Patchett, A.A. (1980) Inactivation of 3-(3,4-dihydroxyphenyl) alanine decarboxylase by 2-(fluoromethyl)-3-(3,4-dihydroxyphenyl)alanine. Biochemistry, 19, 709-718.
90. Nicotra, A., Pierucci, F., Parvez, H., and Senatori, O. (2004) Monoamine oxidase expression during development and aging. Neurotoxicology, 25, 155-165.
91. Nissinen, E., Linden, I.B., Schultz, E., Kaakkola, S., Mannisto, P.T., and Pohto, P. (1988) Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat [published erratum appears in European Journal of Pharmacology 1988 Nov 22; 157(2-3):244]. European Journal of Pharmacology, 153, 263-269.
92. Nissinen, E., Linden, I.B., Schultz, E., and Pohto, P. (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn-Schmiedebergs Archives of Pharmacology, 346, 262-266.
93. Nissinen, E., Kaheinen, P., Penttila, K.E., Kaivola, J., and Linden, I.B. (1997) Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson’s disease, does not impair mitochondrial energy production. European Journal of Pharmacology, 340, 287-294.
94. O’Gara, M., McCloy, K., Malone, T., and Cheng, X. (1995) Structure-based sequence alignment of three AdoMet-dependent DNA methyltransferases. Gene, 157, 135-138.
95. O’Malley, K.L., Harmon, S., Moffat, M., Uhland-Smith, A., and Wong, S. (1995) The human aromatic L-amino acid decarboxylase gene can be alternatively spliced to generate unique protein isoforms. Journal of Neurochemistry, 65, 2409-2416.
96. Olanow, C.W. (2000) Tolcapone and hepatotoxic effects. Archives of Neurology, 57, 263-267.
97. Olanow, C.W. (2006) Rationale for considering that propargylamines might be neuroprotective in Parkinson’s disease. Neurology, 66, S69-S79.
98. Olanow, C.W. and Obeso, J.A. (2000) Preventing levodopa-induced dyskinesias. Annals of Neurology, 47 (4, Suppl 1), S167-S176.
99. Olanow, W., Schapira, A.H., and Rascol, O. (2000) Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends in Neurosciences, 23, S117-S126.
100. Olanow, C.W., Agid, Y., Mizuno, Y., Albanese, A., Bonuccelli, U., Damier, P. et al. (2004) Levodopa in the treatment of Parkinson’s disease: current controversies. Movement Disorders, 19, 997-1005.
101. Palhagen, S., Heinonen, E.H., Hagglund, J., Kaugesaar, T., Kontants, H., Maki-Ikola, O. et al. (1998) Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology, 51, 520-525.
102. Parkinson-Study-Group. (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. New England Journal of Medicine, 321, 1364-1371.
103. Parkinson-Study-Group. (1996a) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Annals of Neurology, 39, 37-45.
104. Parkinson-Study-Group. (1996b) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Annals of Neurology, 39, 29-36.
105. Parkinson-Study-Group. (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Archives of Neurology, 59, 1937-1943.
106. Parkinson-Study-Group. (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Archives of Neurology, 61, 561-566.
107. Parkinson-Study-Group. (2005) A randomized placebo-controlled trial of rasagiline in levodopatreated patients with Parkinson disease andmotor fluctuations: the PRESTOstudy. Archives of Neurology, 62, 241-248.
108. Pletscher, A. and DaPrada, M. (1993) Pharmacotherapy of Parkinson’s disease: research from 1960 to 1991. Acta Neurologica Scandinavica Supplementum, 146, 26-31.
109. Poulikakos, P., Vassilacopoulou, D., and Fragoulis, E.G. (2001) L-DOPA decarboxylase association with membranes in mouse brain. Neurochemical Research, 26, 479-485.
110. Przuntek, H., Conrad, B., Dichgans, J., Kraus, P.H., Krauseneck, P., Pergande, G. et al. (1999) SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. European Journal of Neurology, 6, 141-150.
111. Rascol, O., Brooks, D.J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F. et al. (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet, 365, 947-954.
112. Ribereau-Gayon, G., Danzin, C., Palfreyman, M.G., Aubry, M., Wagner, J., Metcalf, B.W. et al. (1979) In vitro and in vivo effects of alpha-acetylenic DOPA and alpha-vinyl DOPA on aromatic L-amino acid decarboxylase. Biochemical Pharmacology, 28, 1331-1335.
113. Riederer, P., Lachenmayer, L., and Laux, G. (2004) Clinical applications of MAO-inhibitors. Current Medicinal Chemistry, 11, 2033-2043.
114. Salminen, M., Lundstrom, K., Tilgmann, C., Savolainen, R., Kalkkinen, N., and Ulmanen, I. (1990) Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene, 93, 241-247.
115. Schluckebier, G., O’Gara, M., Saenger, W., and Cheng, X. (1995) Universal catalytic domain structure of AdoMet-dependent methyltransferases. Journal of Molecular Biology, 247, 16-20.
116. Schultz, E. and Nissinen, E. (1989) Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochemical Pharmacology, 38, 3953-3956.
117. Sharpless, N.S. and McCann, D.S. (1971) Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral L-dopa. Clinica Chimica Acta, 31, 155-169.
118. Shih, J.C., Chen, K., and Ridd, M.J. (1999) Monoamine oxidase: from genes to behavior. Annual Review of Neuroscience, 22, 197-217.
119. Shinagawa, Y. (1992) Molecular orbital studies on the structure-activity relationships of catechol O-methyltransferase inhibitors. Japanese Journal of Pharmacology, 58, 95-106.
120. Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J.W., LeWitt, P. et al. (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Annals of Neurology, 51, 604-612.
121. Silveira, P., Vaz-Da-Silva, M., Almeida, L., Maia, J., Falcao, A., Loureiro, A. et al. (2003) Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa=benserazide. European Journal of Clinical Pharmacology, 59, 603-609.
122. Sipila, J. and Taskinen, J. (2004) CoMFA modeling of human catechol O-methyltransferase enzyme kinetics. Journal of Chemical Information and Computer Sciences, 44, 97-104.
123. Smith, K.S., Smith, P.L., Heady, T.N., Trugman, J.M., Harman, W.D., and Macdonald, T.L. (2003) In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chemical Research in Toxicology, 16, 123-128.
124. Stocchi, F. (2005) Optimising levodopa therapy for the management of Parkinson’s disease. Journal of Neurology, 252 (Suppl 4), iv43-iv48.
125. Sumi-Ichinose, C., Ichinose, H., Takahashi, E., Hori, T., and Nagatsu, T. (1992) Molecular cloning of genomic DNA and chromosomal assignment of the gene for human aromatic L-amino acid decarboxylase, the enzyme for catecholamine and serotonin biosynthesis. Biochemistry, 31, 2229-2238.
126. Taskinen, J., Vidgren, J., Ovaska, M., Bäckström, R., Pippuri, A., and Nissinen, E. (1989) QSAR and binding model for inhibition of rat liver catechol-O-methyltransferase by 1,5-substituted-3,4-dihydroxybenzenes. Quantitative Structure-Activity Relationships, 8, 210-213.
127. Thebault, J.J., Guillaume, M., and Levy, R. (2004) Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy, 24, 1295-1305.
128. Veser, J. (1987) Kinetics and inhibition studies of catechol O-methyltransferase from the yeast Candida tropicalis. Journal of Bacteriology, 169, 3696-3700.
129. Veser, J., Geywitz, P., and Thomas, H. (1979) Purification and properties of a catechol methyltransferase of the yeast Candida tropicalis. Zeitschrift für Naturforschung C, 34, 709-714.
130. Vidgren, J., Tilgmann, C., Lundstrom, K., and Liljas, A. (1991) Crystallization and preliminary X-ray investigation of a recombinant form of rat catechol O-methyltransferase. Proteins, 11, 233-236.
131. Vidgren, J., Svensson, L.A., and Liljas, A. (1994) Crystal structure of catechol O-methyltransferase. Nature, 368, 354-358.
132. Vilbois, F., Caspers, P., da Prada, M., Lang, G., Karrer, C., Lahm, H.W. et al. (1994) Mass spectrometric analysis of human soluble catechol O-methyltransferase expressed in Escherichia coli. Identification of a product of ribosomal frameshifting and of reactive cysteines involved in S-adenosyl-L-methionine binding. European Journal of Biochemistry, 222, 377-386.
133. Waldmeier, P.C., Baumann, P.A., Feldtrauer, J.J., Hauser, K., Bittiger, H., Bischoff, S. et al. (1990a) CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a noncatechol structure. Naunyn-Schmiedebergs Archives of Pharmacology, 342, 305-311.
134. Waldmeier, P.C., De Herdt, P., and Maitre, L. (1990b) Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat. Journal of Neural Transmission Supplementum, 32, 381-386.
135. Wheeler, D.L., Barrett, T., Benson, D.A., Bryant, S.H., Canese, K., Chetvernin, V. et al. (2006) Database resources of the National Center for Biotechnology Information. Nucleic Acids Research, 34, D173-D180.
136. Winqvist, R., Lundstrom, K., Salminen, M., Laatikainen, M., and Ulmanen, I. (1992) The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI. Cytogenetics and Cell Genetics, 59, 253-257.
137. Youdim, M.B. and Bakhle, Y.S. (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. British Journal of Pharmacology, 147 (Suppl 1), S287-S296.
138. Youdim, M.B., Gross, A., and Finberg, J.P. (2001) Rasagiline [N-propargyl-1R(þ)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. British Journal of Pharmacology, 132, 500-506.
139. Youdim, M.B., Bar Am, O., Yogev-Falach, M., Weinreb, O., Maruyama, W., Naoi, M. et al. (2005) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. Journal of Neuroscience Research, 79, 172-179.
140. Youdim, M.B., Edmondson, D., and Tipton, K.F. (2006) The therapeutic potential of monoamine oxidase inhibitors. Nature Reviews Neuroscience, 7, 295-309.
141. Zhu, M.-Y. and Juorio, A.V. (1995) Aromatic L-amino acid decarboxylase: biological characterization and functional role. General Pharmacology, 26, 681-696.
142. Zhu, B.T., Patel, U.K., Cai, M.X.X., and Conney, A.H. (2000) O-methylation of tea polyphenols catalyzed by human placental cytosolic catechol-O-methyltransferase. Drug Metabolism & Disposition, 28, 1024-1030.
143. Zurcher, G., Colzi, A., and Da Prada, M. (1990a) Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. Journal of Neural Transmission Supplementum, 32, 375-380.
144. Zurcher, G., Keller, H.H., Kettler, R., Borgulya, J., Bonetti, E.P., Eigenmann, R. et al. (1990b) Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase:a pharmacological study in rats. Advances in Neurology, 53, 497-503.